FDA Approves Atezolizumab for ctDNA-Positive Muscle-Invasive Bladder Cancer

The US Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) and atezolizumab plus hyaluronidase-tqjs (Tecentriq Hybreza) for the adjuvant treatment of adults with muscle-invasive bladder cancer (MIBC) following cystectomy. The approval specifically targets patients who exhibit circulating tumor DNA (ctDNA) molecular residual disease (MRD), as identified by an FDA-authorized diagnostic test.

In a simultaneous move, the FDA approved the Signatera CDx (Natera, Inc.) as the companion diagnostic device required to identify eligible patients. This regulatory milestone marks a shift toward precision monitoring in the post-surgical setting for bladder cancer.

Clinical trial data: IMvigor011

The approval is supported by results from the IMvigor011 (NCT04660344) trial, a multi-center, randomized, double-blind, placebo-controlled study. The trial enrolled 250 patients with MIBC who underwent radical cystectomy with lymph node dissection. To be eligible, patients had to have MRD detected via serial ctDNA blood evaluations during the 12 months following surgery, beginning at least six weeks post-operation.

Participants were randomized 2:1 to receive either 1680 mg of atezolizumab intravenously or a placebo every four weeks. Treatment duration lasted up to one year (12 cycles) or until disease recurrence or unacceptable toxicity occurred.

The primary efficacy endpoint was investigator-assessed disease-free survival (DFS), with overall survival (OS) serving as an additional outcome measure. Data revealed a statistically significant improvement in DFS for the atezolizumab arm:

• Median DFS: 9.9 months (95% CI: 7.2, 12.7) for atezolizumab vs 4.8 months (95% CI: 4.1, 8.3) for placebo.
• Hazard Ratio (HR): 0.64 (95% CI: 0.47, 0.87; $P = .0047$).

Improvements in OS were also statistically significant:

• Median OS: 32.8 months (95% CI: 27.7, NE) for atezolizumab vs 21.1 months (95% CI: 14.7, NE) for placebo.
• Hazard Ratio (HR): 0.59 (95% CI: 0.39, 0.90; $P = .0131$).

Safety profile and precautions

The prescribing information for both the intravenous and subcutaneous formulations includes boxed warnings and precautions common to the checkpoint inhibitor class. Oncology nurses should monitor patients for immune-mediated adverse reactions, which can affect any organ system. Other documented risks include infusion-related reactions, embryo-fetal toxicity, and complications associated with allogeneic hematopoietic stem cell transplantation.

Nursing Considerations for Administration

The FDA approval covers two distinct administration routes, offering flexibility for both clinical workflow and patient preference:

• Intravenous Atezolizumab: Dosing schedules include 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks.
• Subcutaneous Atezolizumab and Hyaluronidase-tqjs: This formulation includes 1875 mg of atezolizumab and 30,000 units of hyaluronidase administered every 3 weeks.

For both formulations, treatment is recommended for up to one year unless recurrence or toxicity intervenes.

The Role of Companion Diagnostics

A critical component of this new treatment paradigm is the integration of serial testing. Patients who initially test negative via the Signatera CDx should not receive the immunotherapy immediately; instead, they are advised to continue serial testing. If a patient tests positive for ctDNA MRD within the 12-month post-surgical window, they then become eligible for adjuvant atezolizumab.

This application was granted Priority Review, a designation reserved for drugs that offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. The review was further facilitated by the use of the Assessment Aid, a voluntary submission from the manufacturer to streamline the FDA’s evaluation process.

Reference

1. FDA approves atezolizumab as adjuvant treatment for muscle-invasive bladder cancer patients with molecular residual disease. News release. US Food and Drug Administration; May 15, 2026. Accessed May 15, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-muscle-invasive-bladder-cancer-patients-molecular